C4 Therapeutics (CCCC) Current Assets (2019 - 2026)
C4 Therapeutics (CCCC) posted quarterly Current Assets of $245.4 million for Q1 2026, up 5.52% year-over-year from $232.5 million in Q1 2025, and down 4.94% quarter-over-quarter from $258.1 million in Q4 2025.
C4 Therapeutics (CCCC) Current Assets (2019 - 2026) Analysis & Trends
C4 Therapeutics' Current Assets history runs 8 years deep, the most recent figure standing at $245.4 million for Q1 2026.
- In Q1 2026, Current Assets rose 5.52% year-over-year to $245.4 million; the TTM figure through Mar 2026 stood at $245.4 million (up 5.52% YoY), while the FY2025 annual figure was $258.1 million, changed 0.13% from the prior year.
- Current Assets for Q1 2026 stood at $245.4 million, down from $258.1 million in the prior quarter.
- The five-year high for Current Assets was $325.5 million in Q3 2022, with the low at $206.9 million in Q3 2025.
- The 5-year median for Current Assets is $273.2 million (2024), against an average of $266.8 million.
- The sharpest annual moves came in 2022 and 2024: Current Assets sank 33.34% in 2022, then gained 22.15% in 2024.
- C4 Therapeutics' Current Assets stood at $287.6 million in 2022, then fell by 5.69% to $271.2 million in 2023, then declined by 4.95% to $257.8 million in 2024, then climbed by 0.13% to $258.1 million in 2025, then decreased by 4.94% to $245.4 million in 2026.
- Business Quant data shows CCCC's Current Assets at $245.4 million in Q1 2026, $258.1 million in Q4 2025, and $206.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | C4 Therapeutics | 521.12 Mn | 267.46 Mn | - | 262.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 262.90 Mn |
| Mar 31, 2026 | 245.37 Mn |
| Dec 31, 2025 | 258.11 Mn |
| Sep 30, 2025 | 206.86 Mn |
| Jun 30, 2025 | 224.73 Mn |
| Mar 31, 2025 | 232.54 Mn |
| Dec 31, 2024 | 257.77 Mn |
| Sep 30, 2024 | 273.23 Mn |
| Jun 30, 2024 | 276.04 Mn |
| Mar 31, 2024 | 279.59 Mn |
| Dec 31, 2023 | 271.19 Mn |
| Sep 30, 2023 | 223.69 Mn |
| Jun 30, 2023 | 274.39 Mn |
| Mar 31, 2023 | 278.45 Mn |
| Dec 31, 2022 | 287.56 Mn |
| Sep 30, 2022 | 325.46 Mn |
| Jun 30, 2022 | 318.37 Mn |
| Mar 31, 2022 | 302.95 Mn |
| Dec 31, 2021 | 325.69 Mn |
| Sep 30, 2021 | 412.29 Mn |